PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GILD vs. BMY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between GILD and BMY is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

GILD vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

0.00%10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
27.91%
34.84%
GILD
BMY

Key characteristics

Sharpe Ratio

GILD:

0.46

BMY:

0.59

Sortino Ratio

GILD:

0.80

BMY:

1.13

Omega Ratio

GILD:

1.11

BMY:

1.14

Calmar Ratio

GILD:

0.38

BMY:

0.35

Martin Ratio

GILD:

0.77

BMY:

1.45

Ulcer Index

GILD:

14.62%

BMY:

11.49%

Daily Std Dev

GILD:

24.51%

BMY:

28.41%

Max Drawdown

GILD:

-70.82%

BMY:

-70.62%

Current Drawdown

GILD:

-4.85%

BMY:

-24.19%

Fundamentals

Market Cap

GILD:

$115.13B

BMY:

$113.40B

EPS

GILD:

$0.09

BMY:

-$3.58

PEG Ratio

GILD:

0.52

BMY:

1.91

Total Revenue (TTM)

GILD:

$21.18B

BMY:

$35.96B

Gross Profit (TTM)

GILD:

$16.51B

BMY:

$24.67B

EBITDA (TTM)

GILD:

$1.33B

BMY:

$605.00M

Returns By Period

In the year-to-date period, GILD achieves a 0.01% return, which is significantly higher than BMY's -0.06% return. Over the past 10 years, GILD has outperformed BMY with an annualized return of 2.54%, while BMY has yielded a comparatively lower 2.10% annualized return.


GILD

YTD

0.01%

1M

0.36%

6M

28.28%

1Y

11.82%

5Y*

12.52%

10Y*

2.54%

BMY

YTD

-0.06%

1M

1.18%

6M

32.47%

1Y

17.41%

5Y*

0.07%

10Y*

2.10%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

GILD vs. BMY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GILD
The Risk-Adjusted Performance Rank of GILD is 6161
Overall Rank
The Sharpe Ratio Rank of GILD is 6565
Sharpe Ratio Rank
The Sortino Ratio Rank of GILD is 5656
Sortino Ratio Rank
The Omega Ratio Rank of GILD is 5858
Omega Ratio Rank
The Calmar Ratio Rank of GILD is 6666
Calmar Ratio Rank
The Martin Ratio Rank of GILD is 5858
Martin Ratio Rank

BMY
The Risk-Adjusted Performance Rank of BMY is 6565
Overall Rank
The Sharpe Ratio Rank of BMY is 7070
Sharpe Ratio Rank
The Sortino Ratio Rank of BMY is 6565
Sortino Ratio Rank
The Omega Ratio Rank of BMY is 6363
Omega Ratio Rank
The Calmar Ratio Rank of BMY is 6565
Calmar Ratio Rank
The Martin Ratio Rank of BMY is 6464
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

GILD vs. BMY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for GILD, currently valued at 0.46, compared to the broader market-2.000.002.000.460.59
The chart of Sortino ratio for GILD, currently valued at 0.80, compared to the broader market-4.00-2.000.002.004.000.801.13
The chart of Omega ratio for GILD, currently valued at 1.11, compared to the broader market0.501.001.502.001.111.14
The chart of Calmar ratio for GILD, currently valued at 0.38, compared to the broader market0.002.004.006.000.380.35
The chart of Martin ratio for GILD, currently valued at 0.77, compared to the broader market-30.00-20.00-10.000.0010.0020.000.771.45
GILD
BMY

The current GILD Sharpe Ratio is 0.46, which is comparable to the BMY Sharpe Ratio of 0.59. The chart below compares the historical Sharpe Ratios of GILD and BMY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.50AugustSeptemberOctoberNovemberDecember2025
0.46
0.59
GILD
BMY

Dividends

GILD vs. BMY - Dividend Comparison

GILD's dividend yield for the trailing twelve months is around 3.33%, less than BMY's 4.33% yield.


TTM20242023202220212020201920182017201620152014
GILD
Gilead Sciences, Inc.
3.33%3.33%3.70%3.40%3.91%4.67%3.88%3.65%2.90%2.57%1.27%0.00%
BMY
Bristol-Myers Squibb Company
4.33%4.24%4.44%3.00%2.36%3.69%2.55%3.08%2.55%1.95%2.17%2.46%

Drawdowns

GILD vs. BMY - Drawdown Comparison

The maximum GILD drawdown since its inception was -70.82%, roughly equal to the maximum BMY drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for GILD and BMY. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-4.85%
-24.19%
GILD
BMY

Volatility

GILD vs. BMY - Volatility Comparison

The current volatility for Gilead Sciences, Inc. (GILD) is 4.98%, while Bristol-Myers Squibb Company (BMY) has a volatility of 5.84%. This indicates that GILD experiences smaller price fluctuations and is considered to be less risky than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%14.00%AugustSeptemberOctoberNovemberDecember2025
4.98%
5.84%
GILD
BMY

Financials

GILD vs. BMY - Financials Comparison

This section allows you to compare key financial metrics between Gilead Sciences, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab